20:07 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

Amylyx begins Phase II of AMX0035 for ALS

Amylyx Pharmaceutical Corp. (Cambridge, Mass.) began the Phase II CENTAUR trial to evaluate twice-daily oral AMX0035 for 24 weeks in 132 patients with amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. trial will evaluate the...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Financial News

Amylyx Pharmaceutical completes venture financing

Amylyx Pharmaceutical Corp. , Cambridge, Mass.   Business: Neurology   Date completed: 2016-08-22   Type: Venture financing   Raised: $5 million   Investors: Morningside Venture Investments; ALS Investment Fund; private investors; existing investors  ...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Financial News

Amylyx Pharmaceutical completes venture financing

Amylyx Pharmaceutical Corp. , Cambridge, Mass.   Business: Neurology, Inflammation   Date completed: 2015-11-17   Type: Venture financing   Raised: $1.3 million   Investor: Private investors   Note: Amylyx also received $600,000 from ALS Finding...